Overall Survival with PV clinically tested.
In a Letter published in the journal Leukemia, R.T.Silver et al. presented the results of a comprehensive and rigorous piece of research. His group compared a large database of PV patients subject to “deficient healthcare availability, delayed diagnosis or suboptimal management,” with a matched group of PV patients treated at an MPN specialty center. The results: Improved Overall Survival (24.9 vs 15.6 years) in the carefully treated group approximated mortality rates of the general population.
The authors — Richard T. Silver, Khalid Abu-Zeinah, and Joseph M. Scandura, all associated with Weill-Cornell — outline the inherent challenges of PV and successful interventions taken to control the disease.